Primary prevention of atherosclerosis: A clinical challenge for the reversal of epigenetic mechanisms?

Circulation

Volumn 125, Issue 19, 2012, Pages 2363-2373

  Napoli, Claudio ^a,b   Crudele, Valeria ^a   Soricelli, Andrea ^b,c   Al Omran, Mohammed ^d   Vitale, Nicoletta ^e   Infante, Teresa ^b   Mancini, Francesco P ^e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SDN   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e UNIVERSITY OF SANNIO   (Italy)

Author keywords

epigenetics; primary prevention; statins

Indexed keywords

CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; DNA; HISTONE; PRAVASTATIN; ROSUVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DIET THERAPY; DNA METHYLATION; EPIGENETICS; GENOTYPE ENVIRONMENT INTERACTION; HISTONE MODIFICATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; METABOLIC SYNDROME X; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN RESTRICTION; REVIEW;

ATHEROSCLEROSIS; ENVIRONMENT; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS;

EID: 84862095921     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.085787     Document Type: Review

References (121)

1. Rodriguez-Porcel M, Lerman LO, Herrmann J, Sawamura T, Napoli C, Lerman A. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol. 2003;23:885-891. (Pubitemid 36566182)
2. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109(suppl):III-15-III-19. (Pubitemid 38786438)
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
4. Morrison KM, Atkinson SA, Yusuf S, Bourgeois J, McDonald S, McQueen MJ, Persadie R, Hunter B, Pogue J, Teo K; FAMILY investigators. The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis. Am Heart J. 2009; 158:533-539.
5. Napoli C, Cacciatore F. Novel pathogenic insights in the primary prevention of cardiovascular disease. Prog Cardiovasc Dis. 2009;51: 503-523.
6. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999;354:1234-1241. (Pubitemid 29469351)
7. Napoli C, Palinski W. Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications. Eur Heart J. 2001;22:4-9. (Pubitemid 32622180)
8. Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J. 2002;16:1348-1360. (Pubitemid 34913307)
9. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690. (Pubitemid 28007535)
10. Napoli C, Witztum JL, de Nigris F, Palumbo G, D'Armiento FP, Palinski W. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation. 1999;99:2003-2010. (Pubitemid 29183898)
11. Napoli C, Witztum JL, Calara F, de Nigris F, Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ Res. 2000;87:946-952.
12. Palinski W, D'Armiento FP, Witztum JL, de Nigris F, Casanada F, Condorelli M, Silvestre M, Napoli C. Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. Circ Res. 2001;89:991-996. (Pubitemid 34640865)
13. Napoli C, de Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, Palinski W. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation. 2002;105: 1360-1367. (Pubitemid 34260429)
14. Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic? Clin Sci (Lond). 1999;96:421-425. (Pubitemid 29179150)
15. Napoli C, Lerman LO, Sica V, Lerman A, Tajana G, de Nigris F. Microarray analysis: a novel research tool for cardiovascular scientists and physicians. Heart. 2003;89:597-604. (Pubitemid 36606198)
16. Napoli C, Infante T, Casamassimi A. Maternal-fetal epigenetic interactions in the beginning of cardiovascular damage. Cardiovasc Res. 2011;92:367-374.
17. Russo VEA, Martienssen RA, Riggs AD. Epigenetic Mechanisms of Gene Regulation. Plainview, NY: Cold Spring Harbor Laboratory Press; 1996.
18. Bird A. Perceptions of epigenetics. Nature. 2007;447:396-398. (Pubitemid 46816744)
19. Napoli C, Casamassimi A, Crudele V, Infante T, Abbondanza C. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. Future Cardiol. 2011;7:485-497.
20. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669-681. (Pubitemid 46273573)
21. Kim JK, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals. Cell Mol Life Sci. 2009;66:596-612.
22. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293: 1074-1080. (Pubitemid 32758077)
23. Foley DL, Craig JM, Morley R, Olsson CA, Dwyer T, Smith K, Saffery R. Prospects for epigenetic epidemiology. Am J Epidemiol. 2009;169: 389-400.
24. Kangaspeska S, Stride B, Métivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, Benes V, Gannon F, Reid G. Transient cyclical methylation of promoter DNA. Nature. 2008;452:112-115. (Pubitemid 351355094)
25. Métivier R, Gallais R, Tiffoche C, Le Péron C, Jurkowska RZ, Carmouche RP, Ibberson D, Barath P, Demay F, Reid G, Benes V, Jeltsch A, Gannon F, Salbert G. Cyclical DNA methylation of a transcriptionally active promoter. Nature. 2008;452:45-50. (Pubitemid 351355084)
26. Thomson JP, Skene PJ, Selfridge J, Clouaire T, Guy J, Webb S, Kerr AR, Deaton A, Andrews R, James KD, Turner DJ, Illingworth R, Bird A. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature. 2010;464:1082-1086.
27. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25:1010-1022.
28. Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009;10:192-206.
29. Maunake AK, Chepelev I, Zhao K. Epigenome mapping in normal and disease states. Circ Res. 2010;107:327-339.
30. Whitelaw NC Whitelaw E. Transgenerational epigenetic inheritance in health and disease. Curr Opin Gen Dev. 2008;18:273-279.
31. Shukla A, Chaurasia P, Bhaumik SR. Histone methylation and ubiquitination with their cross-talk and roles in gene expression and stability. Cell Mol Life Sci. 2009;66:1419-1433.
32. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE, Lumey LH. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA. 2008;105:17046-17049.
33. Tobi EW, Lumey LH, Talens RP, Kremer D, Putter H, Stein AD, Slagboom PE, Heijmans BT. DNA methylation differences after exposure to prenatal famine are common and timing-and sex-specific. Hum Mol Genet. 2009;18:4046-4053.
34. Kyle UG, Pichard C. The Dutch Famine of 1944-1945: a pathophysiological model of long-term consequences of wasting disease. Curr Opin Clin Nutr Metab Care. 2006;9:388-394. (Pubitemid 44097808)
35. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr. 2000;71:1344S-1352S. (Pubitemid 30230539)
36. Bogdarina I, Welham S, King PJ, Burns SP, Clark AJ. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007;100:520-526. (Pubitemid 46673261)
37. Alkemade FE, van Vliet P, Henneman P, van Dijk KW, Hierck BP, van Munsteren JC, Scheerman JA, Goeman JJ, Havekes LM, Gittenberger-de Groot AC, van den Elsen PJ, DeRuiter MC. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am J Pathol. 2010;176: 542-548.
38. Harris A, Seckl J. Glucocorticoids, prenatal stress and the programming of disease. Horm Behav. 2011;59:279-289.
39. Tomat AL, Costa Mde L, Arranz CT. Zinc restriction during different periods of life: influence in renal and cardiovascular diseases. Nutrition. 2011;27:392-398.
40. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am J Respir Crit Care Med. 2009;180:462-467.
41. Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young. Active and passive tobacco exposure: a serious pediatric health problem: a statement from the Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1994;90: 2581-2590.
42. Ordovás JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol. 2010;7:510-519.
43. Launay JM, Del Pino M, Chironi G, Callebert J, Peoc'h K, Mégnien JL, Mallet J, Simon A, Rendu F. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS ONE. 2009; 4:e7959.
44. Baccarelli A, Wright RO, Bollati V, Tarantini L, Litonjua AA, Suh HH, Zanobetti A, Sparrow D, Vokonas PS, Schwartz J. Rapid DNA methylation changes after exposure to traffic particles. Am J Respir Crit Care Med. 2009;179:572-578.
45. Turunen MP, Aavik E, Ylä-Herttuala S. Epigenetics and atherosclerosis. Biochim Biophys Acta. 2009;1790:886-891.
46. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. PLoS ONE. 2010;5:e9692.
47. Zawadzki C, Chatelain N, Delestre M, Susen S, Quesnel B, Juthier F, Jeanpierre E, Azzaoui R, Corseaux D, Breyne J, Torpier G, Staels B, Van Belle E, Jude B. Tissue factor pathway inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. Atherosclerosis. 2009;204:e4-e14.
48. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman AW, Sussman MS, Ouyang P, Milliken EE, Issa JP. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 1999;43:985-991. (Pubitemid 29413198)
49. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T, Ylä-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol. 1998; 18:157-167. (Pubitemid 28277591)
50. Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomäki S, Airenne K, Jänne J, Ylä-Herttuala S. Local hypomethylation in atherosclerosis found in rabbit EC-SOD gene. Arterioscler Thromb Vasc Biol. 1999; 19:2171-2178. (Pubitemid 29422250)
51. Wierda RJ, Geutskens SB, Jukema JW, Quax PH, van den Elsen PJ. Epigenetics in atherosclerosis and inflammation. J Cell Mol Med. 2010; 14:1225-1240.
52. de Nigris F, Lerman LO, Napoli C. New insights in the transcriptional activity and coregulator molecules in the arterial wall. Int J Cardiol. 2002;86:153-168. (Pubitemid 35284804)
53. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA. 1999;96:11041-11048. (Pubitemid 29487324)
54. Rienzo M, Nagel J, Casamassimi A, Giovane A, Dietzel S, Napoli C. Mediator subunits: gene expression pattern, a novel transcript identification and nuclear localization in human endothelial progenitor cells. Biochim Biophys Acta. 2010;1799:487-495.
55. Casamassimi A, Napoli C. Mediator complexes and eukaryotic transcription regulation: an overview. Biochimie. 2007;89:1439-1446. (Pubitemid 350122855)
56. Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Ebmeier CC, Goossens J, Rahl PB, Levine SS, Taatjes DJ, Dekker J, Young RA. Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010;467:430-435.
57. Malik S, Roeder RG. The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet. 2010; 11:761-772.
58. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res. 2011;108:1002-1016.
59. Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferatoractivated receptor-in atherosclerosis: an update. Circ J. 2011;75: 528-535.
60. Lund G, Zaina S. Atherosclerosis: An epigenetic balancing act that goes wrong. Curr Atheroscler Rep. 2011;13:208-214.
61. Iannelli P, Zarrilli V, Varricchio E, Tramontano D, Mancini FP. The dietary antioxidant resveratrol affects redox changes of PPARalpha activity. Nutr Metab Cardiovasc Dis. 2007;17:247-256. (Pubitemid 46551689)
62. Zhang Y, Luo Z, Ma L, Xu Q, Yang Q, Si L. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med. 2010;25:729-734.
63. Cunnington MS, Keavney B. Genetic mechanisms mediating atherosclerosis susceptibility at the chromosome 9p21 locus. Curr Atheroscler Rep. 2011;13:193-201.
64. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
65. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, Jääskeläinen JE, Kyo Y, Lenk GM, Sakalihasan N, Kostulas K, Gottsäter A, Flex A, Stefansson H, Hansen T, Andersen G, Weinsheimer S, Borch-Johnsen K, Jorgensen T, Shah SH, Quyyumi AA, Granger CB, Reilly MP, Austin H, Levey AI, Vaccarino V, Palsdottir E, Walters GB, Jonsdottir T, Snorradottir S, Magnusdottir D, Gudmundsson G, Ferrell RE, Sveinbjornsdottir S, Hernesniemi J, Niemelä M, Limet R, Andersen K, Sigurdsson G, Benediktsson R, Verhoeven EL, Teijink JA, Grobbee DE, Rader DJ, Collier DA, Pedersen O, Pola R, Hillert J, Lindblad B, Valdimarsson EM, Magnadottir HB, Wijmenga C, Tromp G, Baas AF, Ruigrok YM, van Rij AM, Kuivaniemi H, Powell JT, Matthiasson SE, Gulcher JR, Thorgeirsson G, Kong A, Thorsteinsdottir U, Stefansson K. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217-224. (Pubitemid 351171400)
66. Uno S, Zembutsu H, Hirasawa A, Takahashi A, Kubo M, Akahane T, Aoki D, Kamatani N, Hirata K, Nakamura Y. A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nat Genet. 2010;42:707-710.
67. Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation. 2010;121:1022-1032.
68. Kim DH, Saetrom P, Snøve O Jr, Rossi JJ. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA. 2008;105:16230-16235.
69. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233.
70. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79: 581-588.
71. Miranda RC, Pietrzykowski AZ, Tang Y, Sathyan P, Mayfield D, Keshavarzian A, Sampson W, Hereld D. MicroRNAs: master regulators of ethanol abuse and toxicity? Alcohol Clin Exp Res. 2010;34:575-587.
72. Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernández-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328: 1570-1573.
73. Franci G, Miceli M, Altucci L. Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. Epigenomics. 2010; 2:731-742.
74. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28:1069-1078.
75. Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, Jukema JW. Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J. 2009; 30:266-277.
76. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensinconverting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J. 2011;75: 2151-2159.
77. Langley B, Brochier C, Rivieccio MA. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke. 2009;40:2899-2905.
78. Gerstner T, Bell N, Konig S. Oral valproic acid for epilepsy: long-term experience in therapy and side effects. Exp Opin Pharmacother. 2008; 9:285-292. (Pubitemid 351233735)
79. Shin IS, Kim JM, Kim KL, Jang SY, Jeon ES, Choi SH, Kim DK, SuhW, Kim YW. Early growth response factor-1 is associated with intraluminal thrombus formation in human abdominal aortic aneurysm. J Am Coll Cardiol. 2009;53:792-799.
80. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J. 2003;24: 225-248. (Pubitemid 36207079)
81. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
82. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94: 3171-3182.
83. Tatsukawa M, Sawayama Y, Maeda N, Okada K, Furusyo N, Kashiwagi S, Hayashi J. Carotid atherosclerosis and cardiovascular risk factors: a comparison of residents of a rural area of Okinawa with residents of a typical suburban area of Fukuoka, Japan. Atherosclerosis. 2004;172: 337-343. (Pubitemid 38167544)
84. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001; 104:2815-2819. (Pubitemid 33126656)
85. Kieltyka L, Urbina EM, Tang R, Bond MG, Srinivasan SR, Berenson GS. Framingham risk score is related to carotid artery intima-media thickness in both white and black young adults: the Bogalusa Heart Study. Atherosclerosis. 2003;170:125-130. (Pubitemid 37083570)
86. Abbott A. Project set to map marks on genome. Nature. 2010;463: 596-597.
87. Chernausek SD. Update: consequences of abnormal fetal growth. J Clin Endocrinol Metab. 2012;97:689-695.
88. Lorenzen JM, Martino F, Thum T. Epigenetic modifications in cardiovascular disease. Basic Res Cardiol. 2012;107:1-10.
89. Zhang H, Darwanto A, Linkhart TA, Sowers LC, Zhang L. Maternal cocaine administration causes an epigenetic modification of protein kinase Cgene expression in fetal rat heart. Mol Pharmacol. 2007;71: 1319-1328. (Pubitemid 46658685)
90. Patterson AJ, Chen M, Xue Q, Xiao D, Zhang L. Chronic prenatal hypoxia induces epigenetic programming of PKCgene repression in rat hearts. Circ Res. 2010;107:365-373.
91. Pippal JB, Fuller PJ. Structure-function relationships in the mineralocorticoid receptor. J Mol Endocrinol. 2008;41:405-413.
92. Friso S, Pizzolo F, Choi SW, Girelli D, Guarini P, Martinelli N, Stanzial AM, Corrocher R, Olivieri O, Friso S. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis. 2008;199:323-327.
93. Guan J, Mao C, Xu F, Geng C, Zhu L, Wang A, Xu Z. Prenatal dehydration alters renin-angiotensin system associated with angiotensin-increased blood pressure in young offspring. Hypertens Res. 2009; 32:1104-1111.
94. Keys A, Anderson JT, Grande F. Prediction of serum-cholesterol responses of man to changes in fats in the diet. Lancet. 1957;273: 959-966.
95. Mancini M, Stamler J. Diet for preventing cardiovascular diseases: light from Ancel Keys, distinguished centenarian scientist. Nutr Metab Cardiovasc Dis. 2004;14:52-57. (Pubitemid 38569425)
96. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, Djordjevic BS, Dontas AS, Fidanza F, Keys MH, Kromhout D, Nedeljkovic S, Punsar S, Seccareccia F, Toshima H. The diet and 15-year death rate in the Seven Countries Study. Am J Epidemiol. 1986;124:903-915. (Pubitemid 17207259)
97. Young F, Capewell S, Ford ES, Critchley JA. Coronary mortality declines in the US between 1980 and 2000: quantifying the contributions from primary and secondary prevention. Am J Prev Med. 2010;39: 228-234.
98. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41:279-281.
99. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham study. N Engl J Med. 1984;311:1144-1147. (Pubitemid 14012581)
100. Stamler J. George Lyman Duff Memorial Lecture: lifestyles, major risk factors, proof and public policy. Circulation. 1978;58:3-19. (Pubitemid 8376653)
101. Bhupathiraju SN, Katherine L, Tucker KL. Coronary heart disease prevention: nutrients, foods, and dietary patterns. Clin Chim Acta. 2011; 412:1493-1514.
102. Franklin BA, Brinks J, Sternburgh MS. Move more, sit less: a first-line, public health preventive strategy? Prev Cardiol. 2010;13:203-208.
103. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999; 282:2340-2346. (Pubitemid 30013066)
104. Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol. 2010;13:84-90.
105. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2009. AHRQ publication No. 09-05129-EF-1.
106. Rosendorff C. Hypertension and coronary artery disease: a summary of the American Heart Association scientific statement [published correction appears in J Clin Hypertens (Greenwich). 2007;9:976]. J Clin Hypertens (Greenwich). 2007;9:790-795.
107. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-1163. (Pubitemid 44444932)
108. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, Uchiyama S, Nakamura H; MEGA Study Group. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008;117: 494-502.
109. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
110. Napoli C, Lerman LO, de Nigris F, Gossl M, Balestrieri ML, Lerman A. Rethinking primary prevention of atherosclerosis-related diseases. Circulation. 2006;114:2517-2527. (Pubitemid 44901525)
111. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
112. Ross J Jr. Left ventricular function after coronary artery reperfusion. Am J Cardiol. 1993;72:91G-97G. (Pubitemid 24023492)
113. Schröder M, Sutcliffe L. Consequences of stress in the secretory pathway: the ER stress response and its role in the metabolic syndrome. Methods Mol Biol. 2010;648:43-62.
114. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361.
115. Kone R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease: a perspective. Drug Des Devel Ther. 2010;4:383-413.
116. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, Patel S, Card DJ, Hermanowski-Vosatka A, Bergstrom JD, Sparrow CP, Detmers PA, Chao YS. Infectious agents are not necessary for murine atherogenesis. J Exp Med. 2000;191:1437-1442.
117. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD; Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290:1459-1466. (Pubitemid 37430400)
118. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. N Engl J Med. 2005;352:1646-1654.
119. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637-1645. (Pubitemid 40530230)
120. Carpinteyro-Espín P, Jacinto-Ruíz S, Caballero-Vazquez P, Alvarado-Caudillo Y, Lund G, Rodríguez-Rios D, Martínez- García JA, Wrobel K, Wrobel K, Zaina S. Organomegaly and tumors in transgenic mice with targeted expression of HpaII methyltransferase in smooth muscle cells. Epigenetics. 2011;6:333-343
121. Napoli C. Developmental mechanisms involved in the primary prevention of atherosclerosis and cardiovascular disease. Curr Atheroscler Rep. 2011;13:170-175.